Abstract
Introduction. The management issues of transplant patients with hepatitis C virus (HCV) are complex, and interferon therapy is often ineffective. We present data from a retrospective review in liver-transplant recipients suffering from HCV recurrence that were treated with pegylated alpha-2b interferon and ribavirin. Methods. A retrospective review of transplant recipients that received combination pegylated alpha-2b interferon (1.5 mcg/kg/wk) and ribavirin (400-600 mg/day) therapy intended for at least 48 weeks. Complications were recorded and included neutropenia (
Original language | English |
---|---|
Pages (from-to) | 1303-1307 |
Number of pages | 5 |
Journal | Transplantation |
Volume | 78 |
Issue number | 9 |
DOIs | |
Publication status | Published - Nov 15 2004 |
Keywords
- Fulminant hepatic failure
- Hepatitis B virus
- Hepatitis C virus
- Interferon
- Orthotopic liver transplantation
ASJC Scopus subject areas
- Transplantation
- Immunology